Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

NCT ID: NCT03603795

Last Updated: 2024-10-29

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-11
• Study Completion Date: 2026-07-30

Brief Summary

Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction chemotherapy. A phase II multicenter and randomized placebo-controlled study

Detailed Description

Subjects will be randomized 1:1 to receive Eltrombopag or matching placebo, in double blinded.

To compare overall survival rate at 12 months between the two arms, with or without 200 mg of Eltrombopag daily after induction chemotherapy

Arm A : Eltrombopag 200 mg (100 mg/day for east Asian heritage) once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)

Arm B : Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L. (maximum day 45)

Conditions

Acute Myeloid Leukemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

A

55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.

Chemotherapy administration would be performed among standard practice:

• Daunorubicin: 60 mg/m² D1 to D3
• Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
• Lomustine (CCNU): 200 mg/m² per os, at D1.

200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.

Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products.

Group Type: EXPERIMENTAL

Eltrombopag

Intervention Type: DRUG

Eltrombopag concomitant with induction chemotherapy in patient with AML

B

55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)

Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.

Chemotherapy administration would be performed among standard practice:

• Daunorubicin: 60 mg/m² D1 to D3
• Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
• Lomustine (CCNU): 200 mg/m² per os, at D1.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo concomitant with induction chemotherapy patients with AML

Interventions

Eltrombopag

Eltrombopag concomitant with induction chemotherapy in patient with AML

Intervention Type: DRUG

Placebo

Placebo concomitant with induction chemotherapy patients with AML

Intervention Type: DRUG

Other Intervention Names

Arm Eltrombopag; Arm experimental A; Arm placebo; Arm B

Eligibility Criteria

Inclusion Criteria

• 60 years of age.
• AML de novo, except AML 3 and AML 7.
• AML with no adverse cytogenetic according to Medical Research Council (MRC) 2010 classification.
• Subjects should be eligible for intensive chemotherapy by Daunorubicine, cytarabine, Lomustine.
• Eastern Cooperative Oncology Group (ECOG) < 3 (appendix 1).
• SORROR ≤ 3 (appendix 2).
• Adequate baseline organ function defined by the criteria below:

• Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN) range except cases clearly not indicative of inadequate liver function
• Alanine Aminotransferase (ALAT) and Aspartate Aminotransferase (ASAT) ≤ 3 x ULN
• Creatinin ≤ 1.5 x ULN
• Adequate cardiac function with Left Ventricular Ejection fraction (LVEF) ≥50%
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
• Women will be menopausal to be enrolled
• The patient must give written (personally signed and dated) informed consent before completing any study-related procedure which means assessment or evaluation that would not form part of the normal medical care of the patient and before the start of induction chemotherapy.
• Affiliated to the French Social Security (Health Insurance).

Exclusion Criteria

• Subjects with a diagnosis of acute promyelocytic (M3) or megakaryocytic leukemia (M7).
• AML with adverse cytogenetic according to the MRC 2010 classification.
• AML secondary to Myelodysplastic syndrome (MDS), Myeloproliferative neoplasm (MPN)
• Clinical symptoms suggesting active central nervous system leukemia, or presence of extramedullary AML.
• Previous exposure to anthracycline.
• Previous AML treatment other than hydroxyurea.
• Treatment with an investigational drug within 30 days or 5 half-life whichever is longer, preceding the first dose of study medication.
• History of thromboembolic event or other condition requiring ongoing use of anticoagulation either with warfarin or low molecular-weight heparin.
• History of another malignancy within the past three years except basal cell carcinoma of the skin or carcinoma in situ of the cervix.
• Pre-existing cardiovascular disease (including congestive heart failure, New York Heart Association (NYHA) Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc >450 msec (QTc >480 msec for subjects with Bundle Branch Block).
• Patient requiring platelets transfusion with platelets > 10 x 10 Giga/L, for whatever reason.
• History of treatment with romiplostim or other Thrombopoietin receptor (TPO-R) agonists.
• Uncontrolled active infection.
• Any serious medical condition, laboratory abnormality, or psychiatric illness that would place the participant at an unacceptable risk or prevent them from giving informed consent.
• Known active HIV, Hepatitis B or C infection.
• Pregnancy or breastfeeding.

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

French Innovative Leukemia Organisation

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Arnaud PIGNEUX, MD PD

Role: PRINCIPAL_INVESTIGATOR

French Innovative Leukemia Organization (FILO)

Locations

CHU ANGERS - Maladies du sang

Angers, , France

CH de la Côte Basque - Hématologie

Bayonne, , France

CHU Estaing

Clermont-Ferrand, , France

CHU Grenoble - Hématologie Clinique

Grenoble, , France

Institut Paoli-Calmettes - Hématologie 2

Marseille, , France

Hôpital Saint-Eloi - Hématologie Clinique

Montpellier, , France

HOPITAL E. MULLER - Hématologie

Mulhouse, , France

CHU HOTEL DIEU - Hématologie Clinique

Nantes, , France

CHU Caremeau

Nîmes, , France

CHU La Milétrie - Hématologie Clinique

Poitiers, , France

CHU Pontchaillou

Rennes, , France

CHU Hautepierre - Hématologie

Strasbourg, , France

Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie

Toulouse, , France

Sponsor FILO

Tours, , France

CHU de Brabois

Vandœuvre-lès-Nancy, , France

Countries

France

Related Links

http://www.filo-leucemie.org

FILO internet site

Other Identifiers

EPAG 2015

Identifier Type: -

Identifier Source: org_study_id